TR200201769T2 - Prostaglandin bileşimleri ve erkek sertleşme bozukluğunun tedavisi. - Google Patents

Prostaglandin bileşimleri ve erkek sertleşme bozukluğunun tedavisi.

Info

Publication number
TR200201769T2
TR200201769T2 TR2002/01769T TR200201769T TR200201769T2 TR 200201769 T2 TR200201769 T2 TR 200201769T2 TR 2002/01769 T TR2002/01769 T TR 2002/01769T TR 200201769 T TR200201769 T TR 200201769T TR 200201769 T2 TR200201769 T2 TR 200201769T2
Authority
TR
Turkey
Prior art keywords
erectile dysfunction
aliphatic
prostaglandin
ester
treatment
Prior art date
Application number
TR2002/01769T
Other languages
English (en)
Turkish (tr)
Inventor
Yeager James
B�Y�Kt�Mk�N Nad�R
B�Y�Kt�Mk�N Servet
Original Assignee
Nexmed Holdings, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23909154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200201769(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nexmed Holdings, Inc. filed Critical Nexmed Holdings, Inc.
Publication of TR200201769T2 publication Critical patent/TR200201769T2/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
TR2002/01769T 2000-01-10 2001-01-10 Prostaglandin bileşimleri ve erkek sertleşme bozukluğunun tedavisi. TR200201769T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/480,738 US6323241B1 (en) 2000-01-10 2000-01-10 Prostaglandin compositions and methods of treatment for male erectile dysfunction

Publications (1)

Publication Number Publication Date
TR200201769T2 true TR200201769T2 (tr) 2002-11-21

Family

ID=23909154

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01769T TR200201769T2 (tr) 2000-01-10 2001-01-10 Prostaglandin bileşimleri ve erkek sertleşme bozukluğunun tedavisi.

Country Status (20)

Country Link
US (1) US6323241B1 (https=)
EP (1) EP1255552B1 (https=)
JP (2) JP2003519657A (https=)
KR (1) KR100614361B1 (https=)
CN (1) CN1394140A (https=)
AT (1) ATE290383T1 (https=)
AU (1) AU760576C (https=)
BE (1) BE2014C001I2 (https=)
BR (1) BR0107478A (https=)
CA (1) CA2395217C (https=)
DE (1) DE60109274T2 (https=)
ES (1) ES2236245T3 (https=)
HK (1) HK1047700B (https=)
HU (1) HUP0204159A3 (https=)
IL (2) IL150306A0 (https=)
MX (1) MXPA02006758A (https=)
PT (1) PT1255552E (https=)
TR (1) TR200201769T2 (https=)
WO (1) WO2001051053A1 (https=)
ZA (1) ZA200205433B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US20050004226A1 (en) * 1998-12-10 2005-01-06 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
EA008720B1 (ru) * 1998-12-10 2007-06-29 Нексмед (Холдингс), Инк. Применение композиции на основе простагландина для лечения расстройства сексуального возбуждения у женщин
US7105571B2 (en) * 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US20040110843A1 (en) * 2000-01-10 2004-06-10 Nexmed (Holdings), Inc. Methods of treatment of male erectile dysfunction
US6693135B2 (en) * 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20090257956A1 (en) * 2002-01-25 2009-10-15 Ramsey Sallis Treatment Method for Treatment of Erectile Dysfunction and Premature Ejaculation
DK1474143T3 (da) 2002-01-25 2009-01-26 Modular Properties Ltd Fremgangsmåder og sammensætninger til bahandling af mandlig erektil dysfunktion
US20090035221A1 (en) * 2002-01-25 2009-02-05 Ramsey Sallis Methods and Compositions for Treatment of Erectile Dysfunction
MXPA04007828A (es) * 2002-02-15 2004-10-15 Nexmed Holdings Inc Composicion de prostaglandina para eltratamiento de la disfuncion erectil.
CA2493723A1 (en) * 2002-09-06 2004-03-18 Nexmed Holdings, Inc. Methods of treatment of male erectile dysfunction
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
BRPI0408454A (pt) 2003-03-21 2006-04-04 Nexmed Holdings Inc composição tópica, método de tratar a ejaculação precoce, e, uso da composição
KR20050119134A (ko) * 2003-03-21 2005-12-20 넥스메드 홀딩스 인코포레이티드 발기 부전 치료용 프로스타글란딘 조성물
JP2006520788A (ja) * 2003-03-21 2006-09-14 ネックスメド ホールディングス インコーポレイテッド プロスタグランジン組成物による血管形成促進および方法
AU2004227853A1 (en) * 2003-04-02 2004-10-21 Nexmed (Holdings), Inc. Prostaglandin compositions and their use for the treatment of vasospasm
US20050159985A1 (en) * 2003-11-21 2005-07-21 Bertram Carl T. System and method of stratifying intervention groups and comparison groups based on disease severity index scores and ranges
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
EP1784225B1 (en) * 2004-08-19 2016-10-05 Applied Genetics Incorporated Dermatics Biomimetic of evodia rutaecarpa fruit extract for amelioration of inflammation
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
US9005183B2 (en) * 2007-05-16 2015-04-14 Health Knight, Llc System and method for treating erectile dysfunction
EP2646015B1 (en) * 2010-12-02 2020-04-22 Ferring International Center S.A. Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate
WO2012139033A1 (en) 2011-04-07 2012-10-11 Nexmed Holdings, Inc. Methods and compositions for treating raynaud's disease
US10226418B2 (en) 2014-05-12 2019-03-12 Susie Q, Ltd. Arginine-containing topical composition
JP6856532B2 (ja) 2015-01-20 2021-04-07 エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc エルゴリン化合物およびその使用
JP2018502889A (ja) 2015-01-20 2018-02-01 エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc イソエルゴリン化合物およびその使用
EP3266458A1 (en) 2016-07-05 2018-01-10 Fagron B.V. Method and composition and kit for treating erectile dysfunction
EP3630758A1 (en) 2017-06-01 2020-04-08 Xoc Pharmaceuticals, Inc Ergoline derivatives for use in medicine
USD1122263S1 (en) * 2023-02-15 2026-04-14 Amadeus S.A.S. Display screen with animated graphical user interface

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) 1954-02-11 1958-01-07 Anthony P Miller Surgical device
BE790840A (fr) 1971-11-01 1973-04-30 Upjohn Co Solutions de medicaments instables et leur preparation
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4254145A (en) 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents
US4311707A (en) 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
PT97441B (pt) 1990-04-25 1998-08-31 Alza Corp Processo para a preparacao de composicoes farmaceuticas que compreendem agentes vasodilatadores, nomeadamente, nitratos, alcaloides ergoticos ou prostaglandinas, ou agentes vasoconstritores, nomeadamente, alcoois benzilicos ou benzenodiois substituidos ou ainda agentes antiflamatorios esteroides e nao esteroides e dispositivos para a sua administracao transuretral
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5380760A (en) 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
NZ305560A (en) 1995-03-14 1998-11-25 Vivus Inc Method for preventing erectile dysfunction by administering vasoactive agent, particularly a prostaglandin, kit therefor
AU742787B2 (en) * 1997-07-09 2002-01-10 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
EP1027054A4 (en) * 1997-10-28 2002-11-04 Vivus Inc LOCAL CONTRIBUTION OF PHOSPHODIESTERASE INHIBITORS IN THE TREATMENT OF ERECTILE DYSFUNCTION
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6102849A (en) 1999-04-03 2000-08-15 Hakac; John R. Non-surgical penile prosthesis

Also Published As

Publication number Publication date
JP2007302690A (ja) 2007-11-22
IL150306A0 (en) 2002-12-01
AU760576B2 (en) 2003-05-15
EP1255552B1 (en) 2005-03-09
BE2014C001I2 (https=) 2020-01-30
IL150306A (en) 2007-06-03
PT1255552E (pt) 2005-06-30
HK1047700B (en) 2005-05-27
DE60109274D1 (de) 2005-04-14
ZA200205433B (en) 2003-11-26
US6323241B1 (en) 2001-11-27
CA2395217C (en) 2004-10-26
EP1255552A1 (en) 2002-11-13
HUP0204159A3 (en) 2005-03-29
HK1047700A1 (en) 2003-03-07
CN1394140A (zh) 2003-01-29
AU2934901A (en) 2001-07-24
BR0107478A (pt) 2002-09-03
KR20020073498A (ko) 2002-09-26
DE60109274T2 (de) 2006-02-09
CA2395217A1 (en) 2001-07-19
HUP0204159A2 (hu) 2003-04-28
WO2001051053A1 (en) 2001-07-19
JP2003519657A (ja) 2003-06-24
AU760576C (en) 2004-04-08
MXPA02006758A (es) 2008-09-12
ES2236245T3 (es) 2005-07-16
KR100614361B1 (ko) 2006-08-18
ATE290383T1 (de) 2005-03-15

Similar Documents

Publication Publication Date Title
TR200201769T2 (tr) Prostaglandin bileşimleri ve erkek sertleşme bozukluğunun tedavisi.
HU229602B1 (en) Prostaglandin compositions and their use for preparation of medicaments sutable for treatment of male erectile dysfunction
TR200200146T2 (tr) Prostaglandin E1 dağıtımı için topikal bileşimler
DE69933128D1 (de) Pharmazeutische zusammensetzungen zur behandlung von erektiler dysfunktion
ATE209856T1 (de) Zusammensetzung und verfahren zur behandlung der erektilen disfunktion des penis
HRP20020787B1 (hr) Postupak liječenja upotrebom kompleksa ligand-imunogen
ES2164251T3 (es) Vacuna que comprende un conjugado antigeno polisacarido-proteina transportadora y proteina transportadora libre.
EE05191B1 (et) Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine
TNSN08511A1 (en) Lyophilized formulations of anti-egfr antibodies
WO2001085188A3 (en) Use of echinacea as a hematinic agent
AU2001246388A1 (en) Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine
DE69925158D1 (de) Zusammensetzung zur behandlung von verbrennungen
CA2442479A1 (en) Topical compositions for prostaglandin e1 delivery
DE102004014783A1 (de) Gefriergetrocknete Formulierung von Antikörperkonjugaten
MD1878G2 (ro) Metodă de profilaxie a endometritei precoce puerperale
UA36962A (uk) Імплантат для формування об'ємної опорно-рухової культі після енуклеації